Clinical Trial Update: Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating adding SNX-5422 to an established dose of ibrutinib in chronic lymphocytic leukemia was terminated; the update covers efficacy and sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• SNX-5422

Snippet

Sponsor: Esanex Inc. | Conditions: Cancer | Phase 1 | Status: TERMINATED